Bispecific antibody drugs have shown that binding to two targets simultaneously can be a powerful and effective way to treat cancer. Binding to three targets could be even better, and Gilead Sciences ...

Bispecific T-cell engagers are just now stepping into the oncology spotlight, but that’s not stopping one pharma company from investigating the next frontier of the modality. Gilead and Merus have ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Gilead Sciences’ oncology and inflammatory diseases research efforts have identified immune dysregulation as a key area of focus. To that end, the drugmaker is expanding its reach by partnering with a ...

As Gilead Sciences awaits the progression of California state litigation over its alleged delay of safer HIV drugs, the company is biding its time with a proposed $40 million settlement to quell the ...

Gilead's fourth-quarter revenue results were in line with estimates, while earnings fell short. The company's results were impacted by higher total costs and expenses and lower Veklury revenues. The ...